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Abstract 
The integrin family is a group of transmembrane glycoprotein comprised of 19 - and 8 -subunits 
that are expressed in 25 different / heterodimeric combinations on the cell surface. Integrins 
play critical roles in many physiological processes, including cell attachment, proliferation, bone 
remodeling, and wound healing. Integrins also contribute to pathological events such as throm-
bosis, atherosclerosis, tumor invasion, angiogenesis and metastasis, infection by pathogenic mi-
croorganisms, and immune dysfunction. Among 25 members of the integrin family, the v3 is 
studied most extensively for its role of tumor growth, progression and angiogenesis. In contrast, 
the IIb3 is expressed exclusively on platelets, facilitates the intercellular bidirectional signaling 
(“inside-out” and “outside-in”) and allows the aggregation of platelets during vascular injury. The 
IIb3 plays an important role in thrombosis by its activation and binding to fibrinogen especially in 
arterial thrombosis due to the high blood flow rate. In the resting state, the IIb3 on platelets does 
not bind to fibrinogen; on activation, the conformation of platelet is altered and the binding sites of 
IIb3 are exposed for fibrinogen to crosslink platelets. Over the last two decades, integrins have 
been proposed as the molecular targets for diagnosis and therapy of cancer, thrombosis and other 
diseases. Several excellent review articles have appeared recently to cover a broad range of topics 
related to the integrin-targeted radiotracers and their nuclear medicine applications in tumor 
imaging by single photon emission computed tomography (SPECT) or a positron-emitting radi-
onuclide for positron emission tomography (PET). This review will focus on recent developments 
of v3-targeted radiotracers for imaging tumors and the use of IIb3-targeted radiotracers for 
thrombosis imaging, and discuss different approaches to maximize the targeting capability of cyclic 
RGD peptides and improve the radiotracer excretion kinetics from non-cancerous organs. Im-
provement  of  target  uptake  and  target-to-background  ratios  is  critically  important  for  tar-
get-specific radiotracers. 
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1. INTRODUCTION 
Radiopharmaceuticals, which are also called ra-
diotracers, are drugs containing a radionuclide. Ra-
diotracers are used routinely in nuclear medicine for 
diagnosis or therapy of diseases, such as cancer, in-
flammation  and  myocardial  infarction  [1-6].  Radio-
tracers can be classified according to the biodistribu-
tion  characteristics:  those  whose  biodistribution  is 
determined exclusively by their chemical and physi-
cal properties; and those whose biological properties 
are determined by the receptor binding capability of Theranostics 2011, 1 
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radiolabeled  biomolecules.  The  latter  class  is  often 
called  target-specific  radiotracers  [3,  4].  Diagnostic 
radiotracers  are  molecules  labeled  with  either  a 
-emitting  isotope  for  single  photon  emission  com-
puted  tomography  (SPECT)  or  a  positron-emitting 
radionuclide  for  positron  emission  tomography 
(PET), and provide a method of assessing the disease 
or  disease  states  by  SPECT  or  PET.  They  are  also 
useful for monitoring the treatment efficacy of a spe-
cific therapeutic regimen in a noninvasive fashion. 
 
 
 
 
Figure  1.  Schematic  presentation  of  the  target-specific 
radiotracer. Radionuclide is the radiation source. BM is the 
targeting biomolecule for receptor binding. A multidentate 
bifunctional chelator is used for chelation of metallic radi-
onuclides. A spacer is used to bridge the radiometal chelate 
and targeting biomolecule. 
 
 
Fig.  1  shows  the  schematic  illustration  of  the 
target-specific  radiotracers,  which  are  often  radio-
metal complexes of a chelator-biomolecule conjugate. 
In some cases, they can be biomolecules attached with 
a  non-metallic  radionuclide,  such  as  18F  and  123I.  A 
target-specific  radiotracer  is  based  on  the  receptor 
binding  of  the  radiolabeled  receptor  ligand  in  the 
diseased  tissue  [7-20].  The  metal-containing  tar-
get-specific radiotracer can be divided into four parts: 
targeting biomolecule (BM), spacer, bifunctional che-
lating  agent  (BFC),  and  radionuclide.  The  targeting 
biomolecule  serves  as  a  ―carrier‖  for  target-specific 
delivery of radionuclide to the diseased tissue with 
many  targeted  receptors.  The  radiolabeled  receptor 
ligand binds to these receptors with high affinity and 
specificity, resulting in selective uptake of the radio-
tracer. The choice of a radionuclide depends on the 
clinical utility of the radiotracer. Table 1 lists several 
selected radionuclides useful for planar imaging and 
SPECT, along with their nuclear characteristics. For 
SPECT, more than 80% of radiotracers used in nuclear 
medicine departments are  99mTc compounds  mainly 
due to the optimal nuclear properties of 99mTc and its 
easy availability at low cost [1-5]. The 6 h half-life is 
long enough to allow radiopharmacists to carry out 
radiosynthesis and for physicians to collect clinically 
useful images. It is also short enough to permit ad-
ministration  of  20  –  30  mCi  of  99mTc  radiotracer 
without imposing a significant radiation dose to the 
patient. 111In is also widely used in gamma scintigra-
phy (only second to  99mTc in clinical applications). It 
decays by electron capture and emits two -photons of 
173 and 247 keV (90% and 94% abundance, respec-
tively). 111In radiotracers are often used as the imaging 
surrogates  for  biodistribution  and  dosimetry  deter-
mination of their corresponding therapeutic  90Y ana-
logs, which might be useful for treatment of cancer. 
67Ga is a cyclotron-produced radionuclide, and has a 
half-life of 78 h. 67Ga has little use in the development 
of target-specific radiotracers since  68Ga radiotracers 
offer significant advantages because of the high spa-
tial resolution of PET as compared to that of SPECT. 
Due to the low solution stability of 201Tl(I) complexes, 
201Tl is used exclusively as its chloride salt for myo-
cardial perfusion imaging in the patients with cardi-
ovascular diseases. 
 
 
Table 1. Selected radionuclides for SPECT.  
Radionuclide  Half-life  Mode of 
decay 
Principal  emis-
sion in keV (% 
abundance) 
99mTc  6.01 h    140.5 (87.2) 
123I  13.27 h  EC  159.0 (83.3) 
131I  8.02 d  - &   364.5 (81.2) 
67Ga  3.261 d  EC  93.3 (37.0), 184.6 
(20.4) 
111In  2.805 d  EC  171.3 (90.2), 245.4 
(94.0) 
201Tl  3.038 d  EC  167.4 (9.4) 
 
 
Nuclear imaging techniques are widely used for 
clinical applications because of their high sensitivity. 
Nuclear imaging modalities (PET and SPECT) are able 
to determine concentrations of specific molecules in 
the human body in the picomolar range and provide 
enough sensitivity needed to visualize most interac-
tions between physiological targets and receptor lig-
ands.  Many  biomolecules  (monoclonal  antibodies, 
peptides, or non-peptide receptor ligands) have been 
successfully used for target-specific delivery of radi-
onuclides. Among them, small peptides with less than 
30  amino  acids  or  molecular  weight  less  than  3500 
Daltons are of particular interest. Compared to mon-
oclonal  antibodies  and  antibody  fragments,  small 
peptides offer several advantages. Peptides are nec-
essary elements in more fundamental biological pro-
cesses than any other class of molecule. They can also Theranostics 2011, 1 
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tolerate harsher conditions for chemical modification 
or radiolabeling. Small peptides are easy to synthesize 
and modify, less likely to be immunogenic, and can 
have rapid blood clearance. The faster blood clearance 
results  in  adequate  T/B  ratios  earlier  so  that  it  is 
practical to use 99mTc, which is the preferred radionu-
clide for diagnostic nuclear medicine. In most cases, 
the  primary  sites  of  interactions  of  peptides  are  re-
ceptors on the outer surface of cell membranes (ex-
tracellular).  All  these  factors  make  small  bioactive 
peptides  excellent  candidates  for  development  of 
target-specific radiotracers. The peptide-based radio-
tracers have been reviewed extensively [7-20]. 
The integrin family is comprised of 25 identified 
members,  which  are  heterodimers  of  19  α-  and  8 
β-subunits  imbedded  non-covalently  into  the  cell 
membrane [21]. The member of this family is still ex-
panding  as  observed  from  human  genome  studies 
[22]. The cell-cell and cell-matrix adhesion processes 
through  binding  of  integrins  to  their  ligands  play 
critical roles in physiological processes, including cell 
attachment,  proliferation  [23-25],  bone  remodeling 
[26], and wound healing [27]. Besides, integrins also 
contribute to pathological events such as thrombosis, 
atherosclerosis [28, 29], tumor invasion, angiogenesis 
and  metastasis  [30-33],  infection  by  pathogenic  mi-
croorganisms [34, 35], and immune dysfunction [36]. 
Therefore,  the  integrins  have  been  proposed  as  the 
molecular targets for the treatment of cancer [37-42], 
thrombosis [43, 44] and other diseases [45, 46] in the 
last two decades. The role of integrins has been re-
viewed extensively [21, 47-50].  
Many integrin family members are crucial to the 
initiation, progression and metastasis of solid tumors. 
Epithelial-derived tumor cells generally retain integ-
rins expressed by epithelial cells including α6β4, α6β1, 
αvβ5, α2β1 and α3β1, and mediate the adhesion, migra-
tion, proliferation and survival of tumor cells. Differ-
ent integrins can promote or suppress the tumor de-
velopment.  For  example,  integrin  α2β1  is 
down-regulated in tumor cells, the phenomenon as-
sociated with increased tumor cell dissemination [51]. 
This  suggests  that  α2β1  could  function  as  a  tumor 
suppressor [52]. On the other hand, the expression of 
αvβ3, αvβ5, α5β1, α6β4, α4β1 and αvβ6 on tumor cells is 
correlated with disease progression in various tumor 
types  [53-58].  More  importantly,  the  expression  of 
integrins  αvβ3,  α5β1  and  αvβ6  are  usually  at  low  or 
undetectable levels in most adult epithelia. Among 25 
members of the integrin family, integrin αvβ3 is stud-
ied most extensively for its role in the tumor growth 
and angiogenesis. While the αvβ3 plays pivotal role in 
the tumor growth and progression, the αIIBβ3 is critical 
for platelet aggregation during thrombosis. It is be-
lieved that the interaction between the tumor αvβ3 and 
platelet αIIbβ3 is also related to the increased tumor 
metastasis via a bridge such as fibrinogen, von Wil-
lebrand factor or thrombospondin [59]. This interac-
tion is believed to facilitate the tumor cell adhesion to 
the vasculature, and often leads to metastasis to var-
ious secondary sites, including bone marrow [60].  
Integrin αIIBβ3 is exclusively expressed on plate-
lets, although αvβ3, α2β1, α5β1 and α6β1 can also medi-
ate platelet adhesion functions [61]. On the surface of 
platelet,  there  are  70~90  thousand  copies  of  αIIBβ3, 
which facilitate the intercellular bidirectional signal-
ing (―inside-out‖ and ―outside-in‖) and allow the ag-
gregation of platelets during the vascular injury. The 
αIIBβ3 plays an important role in thrombosis formation 
by its activation and binding to fibrinogen especially 
in arterial thrombi due to the high blood flow rate. In 
the resting state, the αIIBβ3 on platelets does not bind 
to  fibrinogen.  On  activation,  the  conformation  of 
platelet is altered and the binding sites of αIIBβ3 are 
exposed for fibrinogen to crosslink with the activated 
platelets. Integrin αIIBβ3 antagonists have been widely 
used  in  the  antithrombotic  therapy  in  the  patients 
with percutaneous coronary interventions and unsta-
ble angina [47, 48, 62-65].  
The  αvβ3  and  αIIBβ3  receptor  ligands  share  a 
common RGD tripeptide binding sequence. General-
ly,  linear  RGD  peptides,  such  as  GRGDS 
(Gly-Arg-Gly-Asp-Ser), often have low affinity (IC50 > 
100 nM) and selectivity for αvβ3 and αIIBβ3 [66], and 
undergo rapid degradation in serum by a variety of 
proteases [67, 68]. It has been shown that cyclization 
of  RGD  peptides  via  linkers,  such  as  S-S  disulfide, 
thioether and rigid aromatic rings, often leads to the 
increased  receptor  binding  affinity  and  selectivity 
[67-77]. It has been reported that the αIIBβ3 is less sen-
sitive to variations in the RGD backbone structure and 
can  accommodate  a  larger  distance  or  spacer  than 
αvβ3 and  v5 [66].  On  the  basis  of  extensive  struc-
ture-activity-relationship  studies,  it  was  found  that 
incorporation of the RGD unit into a cyclic the pen-
tapeptide  framework  (Fig.  2:  top)  increases  binding 
affinity and selectivity for v3 over αIIBβ3 [66, 68-77], 
while  addition  of  a  rigid  aromatic  ring  (Fig.  2: 
DMP728  and  DMP757)  into  the  cyclic  hexapeptide 
structure  enhance  the  receptor  binding  affinity  and 
selectivity for αIIBβ3 over both v3 and v5 [66, 79, 
80].  It  was  also  found  that  the  valine  residue  in 
c(RGDfV) could be readily replaced by lysine (K) or 
glutamic  acid  (E)  to  afford  c(RGDfK)  or  c(RGDfE), 
without significantly changing the v3 binding affin-
ity  [69-71].  Similar  behavior  was  also  seen  for 
αIIBβ3-selective hexapeptides [66]. Theranostics 2011, 1 
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Figure 2. Examples of monomeric cyclic RGD peptides. Incorporation of the RGD sequence into a cyclic pentapeptide 
framework increases the binding affinity and selectivity for αvβ3 over v5 and αIIBβ3, while the addition of one or two rigid 
aromatic rings into cyclic hexapeptide structure enhance the binding affinity and selectivity for the αIIBβ3 over αvβ3 and v5.  
 
 
Several excellent review articles have appeared 
recently to cover a broad range of topics related to 
integrin-targeted radiotracers and their nuclear med-
icine  applications  in  tumor  imaging  by  SPECT  and 
PET [81-97]. This review is not intended to be an ex-
haustive review on all radiolabeled cyclic RGD pep-
tides. Instead, it will focus on recent development of 
v3-targeted SPECT radiotracers for imaging tumor 
angiogenesis and the use of the IIb3-targeted radio-
tracers for thrombosis imaging by SPECT. Because of 
the limited space, authors would apologize to those 
whose work has not been presented in detail, and for 
the  omission  of  123I-labeled  cyclic  RGD  peptides  as 
radiotracers in this review. 
2. v3–TARGETED RADIOTRACERS FOR 
TUMOR IMAGING 
Integrin v3 and tumor angiogenesis. Tumor cells 
produce many angiogenic factors, which are able to 
activate  endothelial  cells  on  the  established  blood 
vessels  and  induce  endothelial  proliferation,  migra-
tion,  and  new  vessel  formation  (angiogenesis) 
through a series of sequential but partially overlap-
ping steps [98-103]. Angiogenesis is a key requirement 
for both the tumor growth and metastasis. Without 
the formation of the new blood vessels which provide 
oxygen and nutrients, tumors cannot grow beyond 1 – 
2 mm in size [98, 103]. Angiogenesis is regulated by 
many proteins, such as vascular endothelial growth 
factor (VEGF), vascular endothelial growth factor re-
ceptors  (VEGFR),  G-protein  coupled  receptors  for 
angiogenesis  modulating  proteins,  endogenous  an-
giogenesis inhibitors and integrins [102-105]. Among 
the angiogenesis factors, integrins are responsible for 
the cellular adhesion to extracellular matrix proteins 
in the intercellular spaces and basement membranes 
and subsequent migration of cells, and regulate cel-
lular  entry  and  withdraw  from  cell  cycle  [100, 
107-110].  Among  the  integrins  identified  so  far,  the 
v3 is studied most extensively since serves as a re-
ceptor  for  a  variety  of  extracellular  matrix  proteins 
with  the  exposed  RGD  tripeptide  sequence.  These Theranostics 2011, 1 
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include  vitronectin,  fibronectin,  fibrinogen,  laminin, 
collagen,  von  Willebrand  factor,  and  osteopontin 
[111-119]. The v3 is usually expressed in relatively 
low levels on epithelial cells and mature endothelial 
cells, but is highly expressed in the tumors including 
osteosarcomas,  neuroblastomas,  glioblastomas,  mel-
anomas,  breast,  lung  and  prostate  carcinomas 
[112-120]. Recently, it has been reported that the v3 
is overexpressed on not only tumor cells but also en-
dothelial cells of the tumor neovasculature [121]. The 
v3 expressed on the activated endothelial cells can 
modulate cell adhesion and migration during tumor 
angiogenesis,  and  its  expression  on  carcinoma  cells 
potentiates  metastasis  by  facilitating  invasion  and 
movement of tumor cells across blood vessels [121]. It 
has also been demonstrated that the v3 expression 
level correlates well with the potential for metastasis 
and  the  aggressiveness  of  many  tumors  including 
glioblastomas,  melanoma,  ovarian,  breast  and  lung 
cancers  [113,  119-121].  Therefore,  the  v3  has  been 
identified  as  an  interesting  molecular  target  for  the 
early  diagnosis  of  rapidly  growing  and  metastatic 
tumors [81-97].  
Integrin v3-targeted radiotracers under clinical in-
vestigation.  Many  radiolabeled  cyclic  RGD  peptides 
have been evaluated as the v3-targeted radiotracers 
[122-158]. Significant progress has been made on their 
use in tumor imaging by either SPECT or PET. Among 
the  radiotracers  evaluated  in  many  preclinical  tu-
mor-bearing animal models, [18F]Galacto-RGD (Fig. 3: 
top) and [18F]AH111585 (Fig. 3: middle) are currently 
under clinical investigation for non-invasive imaging 
of  the  v3  expression  in  cancer  patients  [159-164]. 
Imaging studies clearly showed that the accumulation 
of  18F-labeled  RGD  peptide  radiotracers  correlated 
well with the tumor v3 expression levels in cancer 
patients [159-164]. However, their relatively low tu-
mor uptake, high cost and lack of preparative mod-
ules  for  routine  radiosynthesis  will  limit  their  con-
tinued clinical utilities. In addition, several steps  of 
manual radiosynthesis and post-labeling purification 
can  cause  significant  radiation  exposure  to  radio-
pharmacists  in  the  clinics.  99mTc-NC100692  (Fig.  3: 
bottom) is a 99mTc-labeled cyclic RGD peptide mono-
mer  reportedly  to  have  high  integrin  v3  binding 
affinity [165]. In breast cancer patients, 19 of 22 ma-
lignant lesions (86%) were detected by SPECT [165]. 
However, its intensive liver uptake and hepatobiliary 
excretion due to its lipophilic Tc-chelate (Fig. 3) will 
limit its continued clinical applications. Thus, there is 
a  continuing  need  for  more  efficient  v3-specific 
99mTc radiotracers that can be readily prepared from a 
kit formulation at low cost. 
Multimer concept. Since interactions between the 
v3  and  RGD-containing  proteins  (e.g.  vitronectin, 
fibronectin  and  fibrinogen)  may  involve  multiple 
binding sites, the idea to use multimeric cyclic RGD 
peptides  might  provide  more  effective  v3 antago-
nists with tumor targeting capability and hence high-
er cellular uptake for their corresponding radiotracers 
[166]. Multivalent interactions are used in such a way 
that  weak  ligand-receptor  interactions  may  become 
biologically relevant. The multimer concept has been 
used  for  enhancing  the  radiotracer  tumor-targeting 
capability.  For  example,  biodistribution  studies 
showed  that  the  divalent  99mTc-[sc(Fv)2]2  had  ap-
proximately  3-fold  higher  tumor  uptake  than 
99mTc-sv(Fv)2 [167]. The increased binding affinity and 
tumor targeting capability were also reported for the 
125I-labeled divalent recombinant antibody fragment 
[168].  
Multimeric cyclic RGD peptides. To improve v3 
binding  affinity,  dimeric  RGD  peptides,  such  as 
E[c(RGDfK)]2 (Fig. 4: RGD2), have been used to de-
velop the v3-targeted radiotracers. Rajopadhye et al 
were the first to use E[c(RGDfK)]2 to develop diag-
nostic (99mTc and 64Cu) and therapeutic (90Y and 177Lu) 
radiotracers [146-157, 169, 170]. Dijkgraff et al found 
that the tumor uptake of  111In-labeled E[c(RGDfK)]2 
was >2x of that for its corresponding monomeric an-
alog in athymic mice with xenografted SK-RC-52 tu-
mors  [154].  The  same  group  also  reported  the 
DOTA-conjugated cyclic RGD dimers and tetramers 
[154, 155], but no in vivo data was presented. Recent-
ly, Chen and coworkers reported 64Cu and 18F-labeled 
E[c(RGDyK)]2 as PET radiotracers [140, 141]. Poethko 
et  al  also  found  that  the  RGDfE  dimer 
[c(RGDfE)-HEG]2-K (Fig. 4) had much better targeting 
capability  than  the  monomer  c(RGDfE)-HEG 
[128-130].  The  multimer  concept  was  also  used  to 
prepare  cyclic  RGD  tetramers  [142,  144,  153,  155, 
171-173] and octamers [173]. For example, Boturyn et 
al reported a series of cyclic RGDfK tetramers [172], 
and  found  that  increasing  the  peptide  multiplicity 
significantly enhanced the v3 binding affinity and 
internalization. Kessler et al reported a cyclic RGDfE 
tetramer (Fig. 5) that had better v3 binding affinity 
than  its  corresponding  dimer  counterpart  [128-130]. 
Liu et al used E[E[c(RGDfK)]2]2 (Fig. 5: RGD4) for the 
development  of  v3-targeted  diagnostic  (99mTc  and 
64Cu) radiotracers [142, 153]. Chen et al also reported 
the  use  of  64Cu  and  18F-labeled  cyclic  RGD  peptide 
tetramer  E[E[c(RGDyK)]2]2  and  octamer 
E[E[E[c(RGDyK)]2]2]2 for tumor imaging by PET [173]. 
Both the in vitro assays and the ex vivo biodistribu-
tion studies showed that the radiolabeled multimeric 
cyclic  RGD  peptides  had  better  tumor  uptake  with Theranostics 2011, 1 
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longer tumor retention time than their dimeric ana-
logs. However, their T/B ratios were not substantially 
better due to their high uptake in the normal organs 
[173]. It remains unclear if the multimeric cyclic RGD 
peptides,  such  as  E[E[E[c(RGDyK)]2]2]2,  are  really 
multivalent.  Moreover,  the  cost  for  synthesis  of  the 
RGD  octamer  E[E[E[c(RGDyK)]2]2]2  is  prohibitively 
high for future development of the v3-targeted di-
agnostic radiotracers. Thus, an alternate approach is 
needed to improve the v3-targeting capability of the 
radiotracer and minimize its accumulation in normal 
organs. 
 
 
 
Figure 3. Examples of radiolabeled cyclic RGD peptide monomers as radiotracers ([
18F]Galacto-RGD, [
18F]AH111585 and 
99mTc-NC100692) for imaging tumor angiogenesis. They are currently under clinical investigation for noninvasive visualiza-
tion of the αvβ3 expression in cancer patients.  
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Figure 4. Examples of RGD dimers (E[c(RGDfK)]2, E[c(RGDyK)]2 and [c(RGDfE)HEG]2-K) for αvβ3-targeting. 
 
Fiure 5. Structure of a cyclic RGD tetramer [[c(RGDfE)HEG]2K]2-K. Theranostics 2011, 1 
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Figure 6. Schematic illustration of interactions between a 
cyclic RGD tetramer and the integrin v3 receptor.  
Improve αvβ3 binding affinity via bivalency.  Fig.  6 
illustrates the  interaction  between  v3 and a cyclic 
RGD tetramer. The targeting moiety is c(RGDfK). The 
spacer  is  glutamic  acid  (E)  or  its  derivatives.  Two 
factors contribute to the high v3 binding affinity of 
multimeric  cyclic  RGD  peptides:  bivalency  and  the 
enhanced local RGD concentration. The key for biva-
lency is the distance between two adjacent cyclic RGD 
motifs. If this distance is long enough for simultane-
ous v3 binding, the cyclic RGD multimer will bind 
to  v3  in  a  bivalent  fashion.  If  this  distance  is  too 
short, the local  cyclic  RGD peptide concentration is 
still  ―enriched‖  in  the  vicinity  of  neighboring  v3 
sites once the first RGD motif is bound. The combina-
tion of simultaneous v3 binding (bivalency factor) 
and the locally enriched RGD concentration (concen-
tration factor) will result in higher v3 binding affin-
ity for cyclic RGD multimers and better tumor uptake 
with longer tumor retention for their corresponding 
radiotracers. 
To  demonstrate  the  proof-of-principle  for  the 
bivalency concept, Shi et al recently reported a series 
of cyclic RGD dimers (Fig. 7) with G3 (Gly-Gly-Gly) 
and  PEG4  (15-amino-4,7,10,13-tetraoxapentadecanoic 
acid) linkers [174-181]. The G3 and PEG4 linkers were 
used to increase the distance between two RGD motifs 
from 6 bonds in RGD2 to 24 bonds in 3G-RGD2 and 38 
bonds in 3P-RGD2 [174, 175]. The αvβ3 binding affini-
ties (Table 2) against 125I-echistatin bound to U87MG 
human glioma cells follow the order of HYNIC-RGD4 
(IC50 = 7 ± 2 nM) > HYNIC-2P-RGD2 (IC50 = 52 ± 7 nM) 
~ HYNIC-3P-RGD2 (IC50 = 60 ± 4 nM) ~ HYNIC-3G- 
RGD2 (IC50 = 61 ± 2 nM) > HYNIC-P-RGD2 (IC50 = 84 ± 
7  nM)  ~  HYNIC-RGD2  (IC50  =  112  ±  21  nM)  >> 
HYNIC-G-RGD (IC50 = 358 ± 8 nM) > HYNIC-P-RGD 
(IC50 = 452 ± 11 nM). A similar trend was observed for 
their DOTA-conjugates against  125I-c(RGDyK) bound 
to U87MG glioma cells [176]: DOTA-RGD4 (IC50 = 1.3 
± 0.3 nM) ~ DOTA-3P-RGD2 (IC50 = 1.3 ± 0.3 nM) ~ 
DOTA-3G-RGD2 (IC50 = 1.1 ± 0.2 nM) > DOTA-RGD2 
(IC50 = 8.0 ± 2.8 nM) >> DOTA-P-RGD (IC50 = 42.1 ± 
3.5  nM)  ~  c(RGDfK)  (IC50  =  38.5  ±  4.5  nM)  >> 
DOTA-3P-RGK2  (IC50  =  452  ±  11  nM).  These  data 
suggest  that  the  G3  and  PEG4  linkers  between  two 
RGD  motifs  are  responsible  for  the  improved  αvβ3 
binding  affinity  of  HYNIC-3P-RGD2  and 
HYNIC-3G-RGD2  as  compared  to  HYNIC-P-RGD2 
[174,  175].  The  higher  αvβ3  binding  affinity  of 
HYNIC-RGD4 is likely due to the presence of its two 
extra RGD motifs in RGD4 as compared to those in 
HYNIC-3P-RGD2 and HYNIC-3G-RGD2 [174].  
It is important to note that the IC50 values of cy-
clic RGD peptides are largely dependent on the type 
of  assay  (the  immobilized  v3-binding  assay  vs 
whole-cell  v3  competition  assay),  the  radioligand 
(125I-c(RGDyK) vs 125I-echistatin) and tumor cell lines 
(U87MG vs MDA-MB-435). Caution should be taken 
when comparing their IC50 values. Whenever possi-
ble,  a  ―control  compound‖,  such  as  c(RGDfK)  and 
c(RGDyK),  should  be  used  in  each  experiment.  In 
addition, the IC50 values obtained from the in vitro 
assays  cannot  be  used  as  the  ―absolute  proof‖  to 
support the concept of bivalency. They must be used 
in combination with the biodistribution data of their 
corresponding radiotracers. 
To  prove  the  bivalency  of  cyclic  RGD  dimers 
(Fig.  7:  3P-RGD2  and  3G-RGD2),  complexes 
99mTc-3P-RGD2  and  99mTc-3G-RGD2  (Fig.  8)  were 
evaluated in the athymic nude mice bearing U87MG 
human glioma and MDA-MB-435 human breast tu-
mor xenografts [174, 175]. For comparison purposes, 
99mTc-P-RGD2  and  99mTc-RGD4  (Fig.  8)  were  also 
evaluated  using  the  same  tumor-bearing  animal 
models [174, 175]. As expected, the breast tumor up-
take of 99mTc-3P-RGD2 and 99mTc-3G-RGD2 was com-
parable to that of  99mTc-RGD4 (Fig. 8), and was >2x 
higher  than  that  of  99mTc-P-RGD2  [174].  These  data 
strongly suggest that RGD4, 3P-RGD2 and 3G-RGD2 
are  bivalent  and  P-RGD2  is  only  monodentate  in 
binding to the integrin αvβ3 even though it has two 
RGD  motifs.  Similar  conclusion  was  also  made  for 
3P-RGD2 in 64Cu(DOTA-3P-RGD2) [176], 3G-RGD2 in 
64Cu(DOTA-3G-RGD2)  [176],  G3-2P4-RGD2  in 
99mTc-G3-2P4-RGD2 [177], and  2P-RGD2 in their  68Ga 
and 18F radiotracers [178, 179]. If P-RGD2 were biva-
lent, HYNIC-P-RGD2 would have had the same αvβ3 
binding  affinity  as  HYNIC-3P-RGD2  and 
HYNIC-3G-RGD2  while  99mTc-P-RGD2  would  have 
shared  the  same  tumor  uptake  with  99mTc-3P-RGD2 
and 99mTc-3G-RGD2. Theranostics 2011, 1 
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Figure 7. Examples of cyclic RGD dimers with PEG4 and G3 linkers, which are used to increase the distance between two 
RGD motifs and to improve radiotracer excretion kinetics from normal organs. 
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Figure 8. Comparison of the tumor uptake for 
99mTc-P-RGD2, 
99mTc-3G-RGD2, 
99mTc-3P-RGD2 and 
99mTc-RGD4 in the 
athymic nude mice bearing MDA-MB-435 breast cancer xenografts.  
 
Table 2. Integrin αvβ3 binding data for cyclic RGD peptides and their corresponding HYNIC and DOTA conjugates against 
125I-echistatin bound to the αvβ3–positive U87MG human glioma cells. 
Compound  IC50 (nM)  Radiotracer 
c(RGDyK)  458 ± 45   
HYNIC-G-RGD  358 ± 8  [99mTc(HYNIC-G-RGD)(tricine)(TPPTS)] 
HYNIC-P-RGD  452 ± 11  [99mTc(HYNIC-P-RGD)(tricine)(TPPTS)] 
HYNIC-RGD2  112 ± 21  [99mTc(HYNIC-RGD2)(tricine)(TPPTS)] 
HYNIC-P-RGD2  84 ± 7  [99mTc(HYNIC-P-RGD2)(tricine)(TPPTS)] 
HYNIC-2G-RGD2  60 ± 4  [99mTc(HYNIC-2G-RGD2)(tricine)(TPPTS)] 
HYNIC-2P-RGD2  52 ± 7  [99mTc(HYNIC-2P-RGD2)(tricine)(TPPTS)] 
HYNIC-3G-RGD2  61 ± 2  [99mTc(HYNIC-3G-RGD2)(tricine)(TPPTS)] 
HYNIC-3P-RGD2  62 ± 5  [99mTc(HYNIC-3P-RGD2)(tricine)(TPPTS)] 
HYNIC-RGD4  7 ± 2  [99mTc(HYNIC-RGD4)(tricine)(TPPTS)] 
DOTA-RGD2  102 ± 5  64Cu(DOTA-RGD2)/111In(DOTA-RGD2) 
DOTA-3G3-RGD2  74 ± 3  64Cu(DOTA-3G-RGD2)/111In(DOTA-3G-RGD2) 
DOTA-3PEG4-RGD2  62 ± 6  64Cu(DOTA-3P-RGD2)/111In(DOTA-3P-RGD2) 
DOTA-RGD4  10 ± 2  64Cu(DOTA-RGD4)/111In(DOTA-RGD4) 
NOTA-RGD2  100 ± 3  68Ga(NOTA-RGD2) 
NOTA-2G3-RGD2  66 ± 4  68Ga(NOTA-2G-RGD2) 
NOTA-2PEG4-RGD2  54 ± 2  68Ga(NOTA-2P-RGD2) Theranostics 2011, 1 
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Impact  of  radiometal  chelate  on  tumor  uptake  and 
pharmacokinetics. Shi et al [180, 181] also prepared the 
cyclic  RGD  conjugates:  MAG2-3P-RGD2  and 
MAG2-3G-RGD2.  It  was  found  that 
99mTcO(MAG2-3P-RGD2)  had  better  tumor  uptake 
than 99mTc-3P-RGD2 [180], while their liver and kidney 
uptake was almost identical at >60 min p.i. On the 
other  hand,  99mTcO(MAG2-3G-RGD2)  had  the  same 
tumor uptake as 99mTc-3G-RGD2 at <60 min p.i., but its 
liver and kidney uptake was much lower than that of 
99mTc-3G-RGD2  [181].  Among  99mTc-labeled  cyclic 
RGD dimers evaluated in the U87MG glioma-bearing 
model,  99mTcO(MAG2-3P-RGD2)  has  the  highest  gli-
oma uptake (~15 %ID/g over 2 h study period) while 
99mTcO(MAG2-3G-RGD2) has the best tumor/kidney 
(2.49 ± 0.25) and tumor/liver (8.29 ± 1.50) ratios at 120 
min  p.i.  Obviously,  replacing 
[99mTc(HYNIC)(tricine)(TPPTS)]  (M.W.  =  ~1000  Dal-
tons) with 99mTcO(MAG2) (M.W. = ~350 Daltons) had 
a significant impact on both tumor uptake and phar-
macokinetics  of  99mTc  radiotracers.  In  contrast,  sub-
stituting  the  bulky  [99mTc(HYNIC)(tricine)(TPPTS)] 
with  a  much  smaller  and  more  hydrophilic 
111In(DOTA)  chelate  had  little  impact  on  the  radio-
tracer tumor uptake [182, 183]. However, the liver and 
kidney  uptake  of  111In(DOTA-3P-RGD2)  is  signifi-
cantly lower than that of 
99mTc-3P-RGD2, probably due 
to higher hydrophilicity of  111In(DOTA) [82]. Similar 
conclusion  could  be  made  by  directly  comparing 
111In(DOTA-3G-RGD2) and 99mTc-3G-RGD2 [181, 183]. 
111In(DOTA-3P-RGD2)  and  64Cu(DOTA-3P- 
RGD2)  share  the  same  DOTA-conjugate.  The  tumor 
uptake of 111In(DOTA-3P-RGD2) was very close to that 
of 64Cu(DOTA-3P-RGD2) [176, 182]. They also have a 
similar  uptake  in  normal  organs.  For  example,  the 
kidney  uptake  of  111In(DOTA-3P-RGD2)  was  com-
pared well with that of 64Cu(DOTA-3P-RGD2) within 
the  experimental  errors.  The  liver  uptake  of 
111In(DOTA-3P-RGD2)  was  2.52  ±  0.57  %ID/g  at  30 
min  and  1.61  ±  0.06  %ID/g  at  240  min  p.i.,  while 
64Cu(DOTA-3P-RGD2) had the liver uptake of 2.80 ± 
0.35 %ID/g at 30 min p.i. and 1.87 ± 0.51 %ID/g at 240 
min p.i. These data suggest that the radiometal (64Cu 
vs.  111In)  has  little  impact  on  the  radiotracer  tumor 
uptake  and  excretion  kinetics,  probably  due  to  the 
overwhelmingly large size of the dimeric RGD pep-
tides as compared to that of the radiometal chelate. 
The same conclusion was also made by directly com-
paring  the  uptake  in  tumor  and  normal  organs  for 
111In(DOTA-3G-RGD2)  [183]  and  64Cu(DOTA-3G- 
RGD2) [176].  
Integrin  v3  and  RGD  specificity.  The 
αvβ3-specificity  of  99mTcO(MAG2-3P-RGD2)  and 
111In(DOTA-3P-RGD2)  was  demonstrated  by  the 
―blocking experiment‖ (Fig. 9).  
 
 
Figure 9. Comparison of the 60-min biodistribution data in 
the athymic nude mice bearing U87MG glioma xenografts in 
the absence/presence of excess RGD2 to demonstrate its 
αvβ3–specificity  for 
99mTcO(MAG2-3P-RGD2)  (top)  and 
111In(DOTA-3P-RGD2)  (bottom).  The  blockage  of  their 
tumor uptake indicates that the radiolabeled cyclic RGD 
dimers are αvβ3-specific.  
 
The blockage of their tumor uptake indicates that 
they are v3-specific [181, 182]. The uptake blockage 
in eyes, intestine, lungs, liver and spleen suggests that 
their  uptake  in  these  organs  is  partially 
v3-mediated.  The  RGD-specificity  of 
99mTcO(MAG2-3P-RGD2)  and  111In(DOTA-3P-RGD2) 
was demonstrated by comparing their 60-min uptake 
with  that  of  99mTcO(MAG2-3P-RGK2)  and 
111In(DOTA-3P-RGK2), respectively. The dimeric pep-
tide  3P-RGK2  has  the  same  molecular  weight  as 
3P-RGD2;  but  they  have  different  peptide  sequence 
[181, 182]. As expected, replacing the two c(RGDfK) 
moieties  in  3P-RGD2  with  two  c(RGKfD)  motifs  re-
sulted  in  a  much  lower  αvβ3  binding  affinity  of 
MAG2-3P-RGK2  (IC50  =  711  ±  128  nM)  and 
DOTA-3P-RGK2  (IC50  =  715  ±  45  nM)  than  that  of Theranostics 2011, 1 
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MAG2-3P-RGD2  (IC50  =  3.9  ±  0.4  nM)  and 
DOTA-3P-RGD2  (IC50  =  1.3±0.3  nM)  against 
125I-c(RGDyK) bound to the U87MG glioma cells. As a 
result,  99mTcO(MAG2-3P-RGK2)  and 
111In(DOTA-3P-RGK2)  had  much  lower  uptake  as 
compare  to  that  of  99mTcO(MAG2-3P-RGD2)  and 
111In(DOTA-3P-RGD2) in both tumor and normal or-
gans (Fig.  10). These data strongly suggest that the 
localization  of  99mTcO(MAG2-3P-RGD2)  and 
111In(DOTA-3P-RGD2) in the tumor is indeed based on 
interactions between RGD motifs and αvβ3 [181, 182].  
 
   
Figure  10.  Comparison  of  biodistribution  data  of 
99mTcO(MAG2-3P-RGD2)/
99mTcO(MAG2-3P-RGK2)  and 
111In(DOTA-3P-RGD2)/
111In(DOTA-3P-RGK2)  in  athymic  nude  mice  bearing  U87MG  glioma  xenografts  at  60  min 
post-injection. The low tumor uptake for 
99mTcO(MAG2-3P-RGK2) and 
111In(DOTA-3P-RGK2) indicates that the radio-
labeled cyclic RGD dimers are RGD-specific. 
 
 
Multimeric ≠ multivalent. On the basis of the in 
vitro αvβ3 binding assays and the ex-vivo biodistribu-
tion  data,  it  becomes  quite  clear  that  3P-RGD2, 
3G-RGD2  and  RGD4  are  bivalent  in  binding  to  the 
αvβ3.  However,  it  remains  unclear  if  RGD4  will  be-
come tetravalent if a number of G3 or PEG4 linkers are 
incorporated between its four cyclic RGD motifs. To 
answer  this  fundamental  question,  two 
DOTA-conjugated cyclic peptide RGD tetramers (Fig. 
11:  6P-RGD4  and  6G-RGD4)  have  been  successfully 
prepared [183, 184]. Fig. 12 compares the tumor up-
take  of  111In-labeled  RGD  dimers  (3P-RGD2  and 
3G-RGD2) and tetramers (6P-RGD4 and 6G-RGD4) in 
the athymic nude mice bearing U87MG glioma xeno-
grafts.  The  fact  that  111In(DOTA-3P-RGD2)  and 
111In(DOTA-6P-RGD4)  shared  a  very  similar  initial 
tumor uptake within the experimental errors suggests 
that 6P-RGD4 and 6G-RGD4 may not be truly tetrava-
lent [183, 184].  
As discussed previously, both bivalency and the 
locally enhanced RGD concentration contribute to the 
high  v3  binding  affinity  of  multimeric  RGD  pep-
tides. The concentration factor exists in all multimeric 
RGD peptides regardless of spacers or linkers.  The 
key for bivalency is the distance between two RGD 
motifs.    For  example,  this  distance  in  3P-RGD2  (38 
bonds) and 3G-RGD2 (26 bonds) is long enough for 
them to achieve bivalency, which leads to higher v3 Theranostics 2011, 1 
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binding  affinity  of  DOTA-3P-RGD2  and 
DOTA-3G-RGD2 than that of DOTA-RGD2 (Table 2), 
and  higher  tumor  uptake  of111In(DOTA-3P-RGD2) 
and  111In(DOTA-3G-RGD2)  than  that  of 
111In(DOTA-P-RGD2) [139].  In contrast, the concen-
tration factor might be responsible for the longer tu-
mor retention times (Fig. 13) of 111In(DOTA-6G-RGD4) 
as compared to that of 111In(DOTA-3G-RGD2). Even if 
6P-RGD4 and 6G-RGD4 are not tetravalent, the mere 
presence of two extra RGD motifs definitely helps to 
improve the radiotracer tumor retention time, which 
may become important for 90Y and 177Lu radiotracers, 
which have great potential for systemic radiotherapy 
of the αvβ3-positive tumors. 
It must be noted that the ability of a multimeric 
RGD  peptide  to  achieve  bivalency  also  depends  on 
the αvβ3 density.  If the αvβ3 density is very high, the 
distance between two neighboring αvβ3 sites will be 
short, which makes it easier for the multimeric cyclic 
RGD  peptide  to  achieve  the  bivalency.    If  the  αvβ3 
density is very low, the distance between two neigh-
boring αvβ3 sites will be very long, and it might be 
more  difficult  for  the  same  multimeric  cyclic  RGD 
peptide to achieve simultaneous v3 binding.   
 
 
Figure 11. DOTA-conjugated cyclic RGD tetramers: DOTA-6P-RGD4 and DOTA-6G-RGD4. Theranostics 2011, 1 
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Figure 12. Direct comparison of the tumor uptake of the 
111In-labeled cyclic RGD dimers (3P-RGD2 and 3G-RGD2) and 
tetramers (RGD4, 6P-RGD4 and 6G-RGD4) in athymic nude mice bearing U87MG human glioma xenografts.  
 
 
 
Figure  13.  The  whole-body  planar  images  of  the  tumor-bearing  mice  administered  with  ~100  Ci  of 
111In(DOTA-6G-RGD4) and 
111In(DOTA-3G-RGD2) at 1, 4, 24 and 72 h p.i. The concentration factor is responsible for the 
longer tumor retention time of 
111In(DOTA-6G-RGD4) (left) as compared to that of 
111In(DOTA-3G-RGD2) (right). 
 
 
3. IIb3–TARGETED RADIOTRACERS FOR 
THROMBOSIS IMAGING 
Cardiovascular diseases and vulnerable plaque. Car-
diovascular diseases are the most frequent causes of 
death  in  the  Western  world.  Atherosclerosis  is  the 
main  cause  of  coronary  and  peripheral  arterial  dis-
eases [185-189]. Atherosclerosis is a chronic and pro-
gressive systemic disease, with a long asymptomatic 
phase,  characterized  by  accumulation  of  lipids,  in-
flammatory  cells  and  connective  tissue  within  the 
intima of arterial wall [187, 189]. The initial pathologic Theranostics 2011, 1 
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abnormality is the fatty streak, due to accumulation of 
lipoproteins  and  macrophages,  which  may  develop 
into a mature atherosclerotic plaque, with a lipid core 
bounded on its lumen side by a fibrous cap containing 
vascular smooth muscle cells and connective tissue. 
Atherosclerosis remains clinically silent until the le-
sion can expand to the point at which it limits flow, 
producing symptoms of reversible ischemia, such as 
angina,  during  periods  of  high  demand  [187-192]. 
Alternatively, the fibrous plaque can erode or rupture, 
resulting in the exposure of subendothelial collagen 
and  lipid  [187,  190],  which  leads  to  activation  of 
platelets and clotting cascade proteins. Platelet acti-
vation upregulates IIb3 (or glycoprotein IIb/IIIa) on 
the platelet surface which, when stimulated, promote 
platelet aggregation [193-199]. Activation of clotting 
factor  proteins  VII  and  XI  results  in  production  of 
thrombin, fibrinogen, and fibrin through the so-called 
extrinsic and intrinsic coagulation pathways, respec-
tively. The result is the formation of thrombus com-
posed of both fibrin and platelets. The consequences 
of  plaque  rupture  range  from  complete  lysis  of  the 
thrombus by endogenous fibrinolytic pathways with 
subsequent healing of the fibrous cap and overlying 
endothelium to the unchecked thrombosis and com-
plete lumen occlusion. Such an event can range from 
being clinically silent at one extreme through precip-
itation of an acute vascular event, such as unstable 
angina,  myocardial  infarction  or  stroke,  to  sudden 
death at the other extreme [188-190]. It is the rupture 
of plaque and formation of a thrombus that causes the 
most serious complications of atherosclerosis, such as 
acute coronary syndromes and stroke [187, 189, 190]. 
In fact, the plaque rupture is responsible for 76% of all 
fatal  heart  attacks  caused  by  coronary  thrombosis 
worldwide [187-190, 196-204]. Thus, early detection of 
the processes underlying progressive plaque destabi-
lization for the purpose of identifying the patients in 
whom rupture of a vulnerable plaque is likely to re-
sult in a clinical event, is of the utmost importance 
[201-205].  Since  the  disruption  of  atherosclerotic 
plaques  is  known  to  initiate  thrombus  formation 
leading to thrombotic and thromboembolic events, it 
has been suggested that the thrombogenicity of ath-
erosclerotic plaques is one of the most promising ap-
proaches  to  detecting  vulnerable  plaques  [189,  190, 
196-205]. From this point of view, the accurate detec-
tion  of  the  intra-arterial  thrombus  noninvasively 
could have significant diagnostic and prognostic im-
plications [201-205].  
Deep vein thrombosis (DVT). DVT is the formation 
of blood clots in veins and is also known as venous 
thromboembolism [14, 65, 206]. DVT occurs when a 
thrombus  forms  in  one  of  large  veins  in  the  lower 
extremities, leading to partially or completely blocked 
blood circulation. The condition may result in health 
complications, such as a pulmonary embolism (PE) or 
death if not diagnosed and treated effectively. A ma-
jority of DVT patients will experience PE (~30% are 
symptomatic, and 40% are asymptomatic and at high 
risk) because the blood clot is unstable and can travel 
to, and lodges in, the lungs. More than 1 million peo-
ple in the United States suffer from DVT blood clots 
every year. Complications from DVT blood clots kill 
almost 300,000 people a year —more than AIDS and 
breast cancer combined [14, 206]. Thus, accurate early 
detection of DVT and PE is highly desirable so that 
various therapeutic regimens can be given.  
Imaging arterial thrombi. To identify healthy sub-
jects at risk for future cardiovascular events, a con-
sensus of experts has recently defined criteria for the 
diagnosis of vulnerable plaques [190, 192]. Major cri-
teria have been established to represent different as-
pects of the rupture-prone plaque. These include the 
calcified  nodules,  yellow  appearance  of  the  plaque, 
intraplaque hemorrhage, thrombogenicity, active in-
flammation and plaque injury. Further major criteria 
include  a  thin  cap,  a  large  lipid  core,  and  luminal 
stenosis  [190,  192,  203].  Although  many  imaging 
techniques are now clinically available for diagnosis 
of  luminal  narrowing,  arterial  occlusion  and  intra-
mural hematoma [201-205], arterial thrombi are  not 
reliably  detected  by  current  diagnostic  methods. 
Coronary angiography remains the gold standard to 
assess vessel lumen narrowing. Other invasive tech-
niques  include  intravascular  coronary  ultrasound, 
coronary  angioscopy,  intravascular  elastography, 
elastography,  thermography,  or  optical  coherence 
tomography  [201-205,  207].  These  techniques  can 
provide anatomic details of plaque size and composi-
tion, but they have the disadvantage of being inva-
sive. MRI and CT have also been used for diagnosis of 
arterial  thrombi;  but  these  two  modalities  are  ana-
tomical and functional [208-213]. It is difficult to dis-
tinguish the ―fresh‖ and ―old‖ thrombi with MRI and 
CT. In contrast, nuclear imaging by SPECT and PET 
has  the  most  potential  to  furnish  functional  infor-
mation on biologic events which determine the risk of 
plaque rupture [201, 203, 205]. Besides their noninva-
sive  nature,  nuclear  medicine  techniques  have  the 
potential  to  evaluate  important  determinants  of 
plaque vulnerability, taking into account specific cel-
lular or biochemical changes that characterize these 
lesions.  Radiolabeled  monoclonal  antibodies  have 
been used to target fibrin or platelets on acute thrombi 
in humans [214-229], but they were expected to have 
very  limited  clinical  usage  due  to  their  long  blood 
circulation time. These limitations can be alleviated by Theranostics 2011, 1 
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using synthetic peptides that are much smaller and 
are  cleared  quickly  from  the  blood  circulation 
[230-232].  Examples  of  99mTc-labeled  small  peptide 
radiotracers  include  99mTc-apcitide  [233-239]  and 
DMP444 [240-255], both of which target IIb3 recep-
tors  on  the  activated  platelets.  99mTc-TP850  is  a 
99mTc-labeled linear peptide targeting the fibrin com-
ponent  of  thrombi  [256].  The  peptide-based  radio-
tracers  for  thrombus  imaging  have  been  reviewed 
extensively [201-205, 257-265].  
Imaging deep vein thrombosis.  Contrast-enhanced 
venography remains the gold standard for diagnosis 
of DVT, but compression ultrasonography is the most 
common technique used to detect DVT in the lower 
extremities.  Pooled  analyses  showed  that  ultraso-
nography has a sensitivity of 96 % and a specificity of 
98 % for proximal vein thrombosis. The primary lim-
itation of these diagnostic procedures is that neither 
technique  can  distinguish  between  chronic  and  un-
stable thrombi [14, 207, 259]. Both contrast venogra-
phy  and  ultrasonography  are  imaging  procedures 
that detect changes in venous anatomy that are caused 
by  the  intraluminal  thrombus  that  is  sufficiently 
formed either to reduce vascular filling with contrast 
medium  or  to  resist  compression.  However,  these 
procedures do not reflect the metabolic activity of the 
clot, and therefore, they may overestimate the pres-
ence of active clots. The sensitivity of ultrasonography 
is also limited by disease-related and technical factors. 
An alternative approach for diagnosis of acute DVT is 
to detect a molecular marker that is not present in old, 
organized DVT.  
99mTc-apcitide: approved for imaging DVT.  One  of 
the  important  components  of  clotting  process  is 
platelet activation, which leads to the expression of 
IIb3  receptors  that  bind  fibrinogen  and  promote 
platelet–platelet  interaction,  resulting  in  platelet  ag-
gregation and the formation of a secure plug. Many 
synthetic  peptides  targeting  the  IIb3  on  activated 
platelets  have  been  successfully  radiolabeled  with 
99mTc. Because of their small size, these radiotracers 
often have very rapid clearance from the blood circu-
lation.  For  example,  99mTc-P280  (Fig.  14: 
99mTc-apcitide) was the first RGD-mimicking peptide 
studied in humans [233]. 99mTc-apcitide was shown to 
specifically bind the IIb3 (IC50 = 0.20 ± 0.11 μM for 
dog platelets as compared with 0.056 ± 0.011 μM for 
human  platelets),  and  to  selectively  accumulate  in 
fresh thrombi [233, 234]. Imaging studies in dogs also 
showed that the thrombus could be readily detected 
with 99mTc-apcitide [234]. A pilot study of 9 patients 
with carotid atherosclerosis showed the uptake in 11 
of 18 carotid arteries after injection of  99mTc-apcitide 
[237,  238].  There  was  only  a  moderate  correlation 
when compared with ultrasound findings. Bates et al 
enrolled patients with newly diagnosed first DVT and 
the patients with previous DVT [235]. It was found 
that  the  sensitivity  and  specificity  of  99mTc-apcitide 
were  92%  and  86%,  respectively,  for  differentiating 
between  the  acute  and  chronic  thrombus  [235]. 
99mTc-apcitide had a sensitivity and specificity of 87% 
and  100%,  respectively,  for  the  patients  with  DVT. 
These data have clearly demonstrated the potential of 
the  99mTc-apcitide  scintigraphy  to  address  the  im-
portant issues in terms of identifying the arterial le-
sions  responsible  for  recent  symptoms.  However, 
99mTc-apcitide  was not particularly useful for detec-
tion of pulmonary embolism (PE) in 83% of the pa-
tients, most likely due to its low thrombus uptake and 
prolonged  radioactivity  accumulation  in  the  blood 
pool and chest region [234].  99mTc-apcitide has been 
approved by FDA (Food and Drug Administration) 
for  imaging  acute  venous  thrombosis  in  the  lower 
extremities of patients. Apcitide (AcuTec™) is availa-
ble commercially as a non-radioactive freeze-dried kit 
that  can  be  labeled  with  99mTc  for  clinical  usage 
[236-239]. 
 
 
 
Figure 14. Structure of
 99mTc-apcitide, a cyclic RGD pep-
tide mimetic specifically binding to the IIb3 expressed on 
fresh thrombi. 
99mTc-apcitide has been approved by FDA for 
diagnosis of DVT in patients. 
 
 
DMP444: clinically useful for imaging DVT. Acti-
vated platelets express  IIb3 receptors which recog-
nize  proteins  and  small  peptides  bearing  the  RGD 
sequences  while non-activated platelets express vir-
tually no IIb3 receptors in their active conformation 
[240]. DMP728 and DMP757 (Fig. 2) were originally 
developed by DuPont Merck Pharmaceuticals as an 
antithrombotic agents and had very high selectivity 
and binding affinity for GPIIb/IIIa with IC50 values in 
the nanomolar range against fibrinogen binding to the 
activated  platelets  [240].  Therefore,  DMP728  and 
DMP757 are excellent biomolecules to target the fresh Theranostics 2011, 1 
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thrombi. Liu and coworkers at DuPont Medical Im-
aging used the 6-aminocaproic acid linker to connect 
DMP757 with a Tc-binding group, and to keep the Tc 
chelate separate from the cyclic RGD motif to mini-
mize the impact of  99mTc-labeling on the binding af-
finity  for  IIb3 [241-247]. The  N2S2  and  N3S-type  of 
BFCs were used for 99mTc-labeling of DMP757. It was 
found that BFCs had a significant impact on thrombus 
uptake  and  excretion  kinetics  of  radiotracers 
[240-244]. DMP444 (Fig. 15: top) was prepared using 
HYNIC as the BFC, tricine and TPPTS as coligands. 
Among  the  99mTc  radiotracers  evaluated  in  various 
models, DMP444 had the best thrombus uptake with 
the  highest  thrombus/blood  and  thrombus/muscle 
ratios  [246].  In  the  AV  shunt  model,  DMP444  was 
rapidly incorporated into thrombi under both venous 
and arterial conditions [246]. In the canine DVT mod-
el,  DMP444  was  able  to  detect  a  growing  venous 
thrombus  (Fig.  15:  bottom)  as  early  as  15  min  p.i. 
DMP444 has a slow blood clearance (45 % of the in-
jected dose at 2 h) and a high thrombus uptake (9.93 ± 
0.52 % ID/g for arterial thrombi; and 2.86 ± 0.37 % 
ID/g for venous thrombi). Mitchel et al [250] tested 
the  ability  of  DMP444  to  identify  platelet-rich 
thrombus  in  a  canine  model,  and  found  that  the 
thrombus radioactivity correlated well with thrombus 
weights.  Kaul’s  group  found  that  the  micro-
throboembli  can  be  detected  after  primary  percuta-
neous transluminal coronary angioplasty (PTCA), and 
the  infarct  size  was  proportional  to  the  magnitude 
and extent of microthroboembli [255]. Thrombus im-
aging during reperfusion may provide important in-
formation in  the  patients with acute  myocardial in-
farction  that  may  lead  to  better  adjuvant  therapy 
during PTCA. In the patients suspected with DVT, no 
clinically significant adverse effects were noted after 
administration  of  DMP444  [253].  Most  of  patients 
were taking Warfarin® (Coumadin®) and heparin (n 
= 8) or Heparin® (n = 1) and Warfarin® (n = 1) alone 
at  the  time  of  imaging.  The  average  time  from  the 
onset of symptoms to injection of DMP444 was 5 days 
(range 1 to 18 days). At 10 – 40 min p.i., 8 of 10 pa-
tients demonstrated an area of the increased radioac-
tivity that was clearly related to the abnormality as 
noted  by  ultrasound  methods  [253].  These  prelimi-
nary data lead to the comprehensive Phase II clinical 
studies. It was concluded that DMP444 is very useful 
for noninvasive imaging of DVT with high sensitivity 
and specificity. In addition, it has also shown that the 
DMP444 SPECT allows in vivo visualization of infec-
tive endocarditis if it is performed within 1 to 2 weeks 
after  antibiotic  treatment  [251].  A  non-radioactive 
freeze-dried kit has been developed, and can be used 
for routine 99mTc-labeling in clinical settings [248, 266]. 
 
Figure  15.  Top:  Structure  of  DMP444;  Bottom:  DVT 
images of a dog administered with DMP444 at 15, 30, 60, 
and 120 min post-infusion. The bar to the right of the im-
ages  indicates  the  scale  from  0  (white)  to  506  (great-
est/black). The phase II clinical studies have demonstrated 
that DMP444 is clinically useful for imaging DVT.  
 
4. SUMMARY AND OUTLOOK 
Radiolabeled  cyclic  RGD  peptides  represent  a 
new  class  of  radiotracers  for  diagnosis  of  tumor  or 
thrombosis, depending upon their selectivity for v3 
or IIb3. While cyclic RGD pentapeptides have high 
binding  affinity  and  selectivity  for  v3,  the  cyclic 
hexapeptides with one or more rigid aromatic rings 
tend to show high binding affinity and selectivity for 
IIb3 over v3/v5. The v3-targeted radiotracers 
have  the  potential  for  early  detection  of  rapidly 
growing and metastatic tumor, and for monitoring the 
tumor  growth,  metastasis  and  therapeutic  response Theranostics 2011, 1 
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by  PET  or  SPECT  [267,  268].  [18F]Galacto-RGD, 
[18F]AH111585  and  99mTc-NC100692  are  currently 
under clinical investigations for noninvasive visuali-
zation of the v3-positive tumors in cancer patients. 
While the research efforts on v3–targeted radiotrac-
ers have been focused on new RGD peptides with the 
improved v3 affinity, the formulation development 
for routine preparation of radiotracers remains to be 
strengthened. It must be emphasized that the success 
of a new v3-targeted radiotracer relies largely on its 
clinical availability at reasonable cost and capability to 
improve  the  quality  of  cancer  patient’s  life.  In  this 
respect,  the  99mTc  radiotracers  will  offer  significant 
advantages because of the nuclear properties of 99mTc 
for SPECT, easy availability of 99Mo-99mTc generators, 
and  the  kit  formulation  for  routine  preparation  of 
99mTc radiotracers at low cost. 
Increasing  the  RGD  peptide  multiplicity  can 
significantly enhance their v3 binding affinity, and 
improve tumor targeting ability of their radiotracers. 
However,  the  tumor  selectivity  is  not  substantially 
improved because the uptake of radiolabeled cyclic 
RGD  peptide  multimers  in  the  intestine,  liver  and 
kidneys  is  also  significantly  increased.  As  a  result, 
there is no significant advantage in using radiolabeled 
tetramers  (such  as  RGD4,  6G-RGD4  and  6P-RGD4) 
over their dimeric counterparts (such as 3G-RGD2 and 
3P-RGD2)  as  diagnostic  radiotracers  with  respect  to 
the tumor selectivity or T/B ratios. Among the cyclic 
RGD  dimers  evaluated  in  different  preclinical  tu-
mor-bearing animal models, 3G-RGD2 and 3P-RGD2 
are the best v3-targeting biomolecules because their 
corresponding PET and SPECT radiotracers tend to 
have excellent tumor uptake with very high T/B ra-
tios. Recently, 99mTc-3P-RGD2 has been selected as a 
candidate for clinical evaluations because of its high 
tumor uptake, long tumor retention and high meta-
bolic stability [174, 175]. 
It  is  important  to  emphasize  that  v3  is  also 
over-expressed  on  the  activated  endothelial  cells 
during wound healing and post-infarction remodel-
ing,  in  rheumatoid  arthritis  and  psoriatic  plaque 
[269-271].  Thus,  the  v3–targeted  radiotracers  de-
veloped for tumor imaging have been proposed for 
imaging  myocardial  angiogenesis.  For  example,  re-
cent  studies  clearly  showed  that  the  111In-labeled 
nonpeptide v3 antagonist (RP748) was able to image 
angiogenesis in the heart after myocardial infarction 
[271], and the radiotracer uptake in the infarct region 
was associated with the level of v3 expression. The 
results  from  imaging  studies  also  suggest  that 
[18F]Galacto-RGD might be a powerful tool to distin-
guish between acute and chronic phases of T-cell me-
diated immune responses [272]. These promising re-
sults give rise to the possibility of extending applica-
tions of the v3–targeted radiotracers from imaging 
tumor  angiogenesis  to  detection  of  inflammatory 
processes, and to monitoring outcomes of therapeutic 
interventions in patients with cancer, myocardial in-
farction, and inflammation.  
While  the  DVT  can  be  detected  by  con-
trast-enhanced  venography  and  compression  ultra-
sonography,  accurate  detection  of  arterial  thrombi 
and  PE  remains  a  significant  challenge  because  of 
their small size and location.  99mTc-apcitide was ap-
proved for diagnosis of DVT; but its T/B ratios are 
low  due  to  its  accumulation  in  the  blood  pool  and 
chest region [246]. DMP444 has higher thrombus up-
take with better T/B ratios than  99mTc-apcitide [240, 
246]. However, its blood  clearance rate is relatively 
slow,  due  to  the  lipophilic  6-aminocaproic  linker 
and/or  the  highly  charged  ternary  ligand  system. 
Therefore,  the  focus  of  future  research  in  this  area 
should be directed towards developing more efficient 
radiotracers that have faster blood clearance and are 
useful for accurate detection of small thrombosis le-
sions in the coronary artery, as well as DVT and PE in 
patients.  The  ―bivalency  concept‖  developed  for 
v3-targeted  radiotracers  may  also  apply  to  cyclic 
RGD  hexapeptides  to  improve  the  IIb3-targeting 
capability.  Since  thrombus  formation  represents  the 
final step in atherosclerosis progression, imaging with 
the v3-targeted radiotracers may be able to not only 
identify those patients at high risk for cardiovascular 
events  (death,  myocardial  infarction  or  stroke)  not 
identified  by  routine  clinical  evaluation,  but  also 
characterize the lesion vulnerability in high-risk areas 
of the coronary vasculature. Once the lesion is deter-
mined  to  be  of  particularly  high  risk,  novel  local 
therapies such as intracoronary drug-eluting stents or 
local drug delivery with suitable drug-delivery bal-
loon catheters could be justified. In addition, molecu-
lar imaging of arterial thrombi will help to select the 
individualized treatment strategies based on the mo-
lecular  profile  of  vulnerable  plaques  identified  in  a 
particular patient. 
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